Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
748.54
-0.90 (-0.12%)
Streaming Delayed Price
Updated: 12:08 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
3 of Wall Street’s Favorite Stocks with Open Questions
August 19, 2025
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...
Via
StockStory
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
August 17, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.
Via
StockStory
Topics
Artificial Intelligence
These S&P500 stocks are moving in today's session
↗
August 14, 2025
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
August 12, 2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was...
Via
StockStory
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
August 12, 2025
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...
Via
StockStory
Topics
Bonds
Economy
Lawsuit
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
↗
August 11, 2025
Truist, however, kept a ‘Buy’ rating on the shares.
Via
Stocktwits
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
↗
August 11, 2025
Via
Benzinga
How Do Investors Really Feel About Regeneron Pharmaceuticals?
↗
August 08, 2025
Via
Benzinga
Regeneron Announces Investor Conference Presentations
August 07, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
↗
August 04, 2025
Via
Benzinga
Beyond The Numbers: 15 Analysts Discuss Regeneron Pharmaceuticals Stock
↗
August 04, 2025
Via
Benzinga
Is Regeneron Pharmaceuticals Gaining or Losing Market Support?
↗
August 04, 2025
Via
Benzinga
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
↗
August 03, 2025
These biotech businesses look compelling for very different reasons.
Via
The Motley Fool
Regeneron (REGN) Q2 EPS Jumps 53%
↗
August 02, 2025
Via
The Motley Fool
Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday?
↗
August 01, 2025
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.
Via
Benzinga
Why Regeneron (REGN) Stock Is Trading Up Today
August 01, 2025
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst...
Via
StockStory
Topics
Artificial Intelligence
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
↗
August 01, 2025
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.
Via
Benzinga
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
↗
August 01, 2025
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.
Via
Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q2 2025 Earnings Estimates but Faces Muted Market Reaction
↗
August 01, 2025
Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B.
Via
Chartmill
Topics
Earnings
Regeneron’s (NASDAQ:REGN) Q2: Strong Sales
August 01, 2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was...
Via
StockStory
Regeneron Reports Second Quarter 2025 Financial and Operating Results
August 01, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
August 01, 2025
Via
Benzinga
Earnings Scheduled For August 1, 2025
↗
August 01, 2025
Via
Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
↗
July 31, 2025
Via
Stocktwits
Topics
Government
Exploring Regeneron Pharmaceuticals's Earnings Expectations
↗
July 31, 2025
Via
Benzinga
Regeneron (REGN) Q2 Earnings: What To Expect
July 30, 2025
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
↗
July 27, 2025
Wall Street might be underestimating these companies' potential.
Via
The Motley Fool
Topics
Stocks
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
↗
July 25, 2025
Via
Benzinga
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
July 24, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Low-Volatility Stocks We Steer Clear Of
July 24, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
